cefotaxime and Foot-Diseases

The efficacy and safety of ceftizoxime and cefoxitin were compared in a randomized, double-blind study of therapy for lower extremity infections in patients with diabetes mellitus or peripheral vascular disease. Overall clinical responses were satisfactory in 82% (23/28) of patients treated with ceftizoxime and in 68% (17/25) of patients treated with cefoxitin. The difference was not statistically significant. Ceftizoxime had superior in vitro activity against Enterobacteriaceae, especially Enterobacter cloacae, whereas cefoxitin had better activity against the Bacteroides fragilis group. Relapses of infection were common in both groups during long-term follow-up; only about one third of patients in either group maintained satisfactory outcomes after one year. More than half of the patients in both groups responded to one or more courses of medical therapy and avoided major amputations for one year following entry into the study.

Topics: Aged; Bacterial Infections; Cefotaxime; Cefoxitin; Ceftizoxime; Clinical Trials as Topic; Diabetes Complications; Double-Blind Method; Female; Follow-Up Studies; Foot; Foot Diseases; Humans; Ischemia; Male; Middle Aged; Prospective Studies; Random Allocation; Recurrence

Topics: Bacterial Infections; Cefotaxime; Ceftizoxime; Clinical Trials as Topic; Foot Diseases; Humans

Primary subacute haematogenous osteomyelitis is one of the causes of limp. It usually involves tubular bones. Flat and small bones are affected less commonly. Diagnosis is difficult and usually takes weeks together for completion. Salmonella spp. can be isolated as a cause of primary subacute haematogenous osteomyelitis, if a usually underlying disorder, such as sickle cell anemia is associated. In this study, we present a child with normal immunity diagnosed as Salmonella primary subacute haematogenous osteomyelitis of the navicular bone, which is a rare condition. Primary subacute haematogenous osteomyelitis must be considered as a cause of limp for timely diagnosis and treatment.

Topics: Acute Disease; Anti-Bacterial Agents; Bacteremia; Cefotaxime; Child, Preschool; Foot Diseases; Humans; Immunity; Immunocompetence; Magnetic Resonance Imaging; Male; Osteomyelitis; Salmonella; Salmonella Infections; Tarsal Bones

Osteomyelitis at the base of an ulcer the foot of diabetic patient is a serious complication usually produced because of the patient's neglect, and entailing difficulties in diagnosis and treatment. Several factors (neurological and vascular ...) favor the onset of the initial ulcer and its evolution, the ulcer subsequently converting into the main door for soft tissue infection with extension to the contiguous bone, with a bad prognosis. Cefotaxime is a 3rd generation cephalosporin, active against coccus gram positive and the majority of aerobic gram negative bacillus. This antibiotic was used in 25 diabetic patients with osteomyelitis at a dosage of 2 gr. IV a/d, during at least 30 days, adding metronidazole when anaerobic bacteria were isolated. The number of patients cured were 21 (84%), one improvement (4%), one resistant (4%) and two relapses (8%). There were no secondary effects.

Topics: Aged; Aged, 80 and over; Cefotaxime; Diabetes Complications; Female; Foot Diseases; Humans; Male; Middle Aged; Osteomyelitis

15 patients with severe diabetic gangrene were treated with a combined intra-arterial PGE1/Cefotaxime infusion therapy. There was no indication for vascular reconstructive surgery. The average treatment took 24.7 days. 11 of the 15 patients were responsive to the therapy. Nevertheless 5 of these 11 patients had to be amputated below-knee in the further course of treatment. In 6 cases we succeeded in preserving the affected extremity in a state of acceptable use. One patient died during the study. No complications due to the therapy were seen. Considering that all patients were near to amputation when entering the study the result to have saved the extremities in 40% of the cases must be regarded as a success.

Topics: Alprostadil; Cefotaxime; Diabetic Angiopathies; Foot; Foot Diseases; Gangrene; Humans; Infusions, Intra-Arterial